AbbVie’s Humira continues to lose market share as biosimilars gain ground

AbbVie’s Humira (adalimumab) remains the biggest player in the anti-inflammatory space but its market share has dropped to 82% since May 2024, according to Samsung Bioepis’ latest biosimilar report released on Thursday.